Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
87%
Rituximab
36%
B Cell
31%
CHOP
29%
Gene Expression Profiling
21%
Pathologist
18%
Diagnosis
16%
Doxorubicin
15%
Prednisone
15%
Cyclophosphamide
15%
Vincristine
15%
Progression Free Survival
15%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
International Prognostic Index
13%
Germinal Center
10%
Neck
10%
Oropharynx Squamous Cell Carcinoma
10%
Multiplex Polymerase Chain Reaction
10%
Rheumatic Disease
10%
DNA (Cytosine 5) Methyltransferase 1
10%
Lymph Node Metastasis
10%
Transient Receptor Potential Channel
10%
Digital Pathology
10%
Head and Neck Cancer
10%
Multilevel Analysis
10%
Overall Survival
10%
Real-Time Polymerase Chain Reaction
9%
Biological Marker
8%
Immunohistochemistry
6%
Leukocyte
5%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Rituximab
45%
Cyclophosphamide
24%
Doxorubicin
24%
Prednisone
24%
Gene Expression Profiling
21%
DNMT1
21%
Progression Free Survival
20%
Protein Expression
13%
Messenger RNA
13%
Immune Response
11%
Synapsin I
10%
TRIM21
10%
Huntingtin
10%
MHC Class II
10%
FOXP2
10%
Quantitative Reverse Transcription Polymerase Chain Reaction
10%
DNMT3A
10%
Multiplex Polymerase Chain Reaction
10%
Myeloid
10%
DNMT3B
10%
Antigen Expression
10%
Overall Survival
10%
FOXP1
9%
LMO2
7%
DNA Methyltransferase
6%
Cancer Cell
6%
Immunology and Microbiology
B Cell
87%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
34%
Rituximab
19%
Cyclophosphamide
17%
Prednisone
17%
Protein Expression
15%
Germinal Center
15%
Overall Survival
14%
Progression Free Survival
12%
Immune Response
12%
Repressor Gene
10%
MHC Class II
10%
Rheumatic Disease
10%
Receptor Potential
10%
Cancer Testis Antigen
10%
Single-Cell Sequencing
10%
Antigen Expression
10%
Prognostic Biomarker
5%
Leukocyte
5%